These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. Panchal NK; Sabina EP Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955 [TBL] [Abstract][Full Text] [Related]
25. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029 [TBL] [Abstract][Full Text] [Related]
26. Expression and function of PIM kinases in osteosarcoma. Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617 [TBL] [Abstract][Full Text] [Related]
27. The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106 [TBL] [Abstract][Full Text] [Related]
28. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles. Chen L; Mao W; Ren C; Li J; Zhang J J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076 [TBL] [Abstract][Full Text] [Related]
30. PIM kinase (and Akt) biology and signaling in tumors. Warfel NA; Kraft AS Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412 [TBL] [Abstract][Full Text] [Related]
31. Targeting the Pim kinases in multiple myeloma. Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558 [TBL] [Abstract][Full Text] [Related]
32. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. An N; Kraft AS; Kang Y J Hematol Oncol; 2013 Jan; 6():12. PubMed ID: 23360755 [TBL] [Abstract][Full Text] [Related]
34. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure. Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687 [TBL] [Abstract][Full Text] [Related]
35. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177 [TBL] [Abstract][Full Text] [Related]
36. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Isaac M; Siu A; Jongstra J Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509 [TBL] [Abstract][Full Text] [Related]